Theriva Biologics (TOVX) Depreciation & Amortization (CF) (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Depreciation & Amortization (CF) of $24000.0 for Q1 2026, down 7.69% year-over-year from $26000.0 in Q1 2025, and down 11.11% quarter-over-quarter from $27000.0 in Q4 2025.
Theriva Biologics (TOVX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $24000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.69% year-over-year to $24000.0; the TTM figure through Mar 2026 stood at $106000.0 (down 14.52% YoY), while the FY2025 annual figure was $108000.0, down 21.17% from the prior year.
- Depreciation & Amortization (CF) eased to $24000.0 in Q1 2026 per TOVX's latest filing, from $27000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $39000.0 in Q4 2023 and bottomed at $18000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $28764.7 across 5 years, with a median of $27000.0 in 2024.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 92.31% in 2022 and fell as far as 45.45% in 2022.
- Theriva Biologics' Depreciation & Amortization (CF) stood at $25000.0 in 2022, then jumped by 56.0% to $39000.0 in 2023, then tumbled by 30.77% to $27000.0 in 2024, then changed by 0.0% to $27000.0 in 2025, then retreated by 11.11% to $24000.0 in 2026.
- Business Quant data shows TOVX's Depreciation & Amortization (CF) at $24000.0 in Q1 2026, $27000.0 in Q4 2025, and $28000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24,000.00 |
| Jun 30, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |